Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

ELANA® Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)

Coordinator
Amt Medical Research BV, Netherlands
Runs
1 October 2022 to 30 September 2025
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
2 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190101904

What the project is doing

In the project's own words, from its summary on CORDIS.

We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with “keyhole” minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA® technology enables reproducible coronary artery bypass grafting (CABG) surgery without the need of heart arrest and suturing, thus avoiding the need to open the patient’s chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether.

By realising closed-chest CABG, ELANA® reduces not only the risks associated with traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA® will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT Medical seeks a total of €7.5M funding (€2.5M grant, €5M equity) to finalise clinical validation and gain market approval.

Topics

Who is involved

OrganisationCityCountryRole
Amt Medical Research BVUtrechtNetherlandsCoordinator
AMT Medical BVEdeNetherlandsThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI